Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01063075 | A Study in Advanced Solid Tumors | completed | Phase 2 | 34 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 26, 2019 | clinicaltrials |
| NCT01099358 | Study in Advanced Solid Tumors | completed | Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 26, 2019 | clinicaltrials |
| NCT01898130 |
| completed |
| Phase 2 |
| 27 |
| Northwestern UniversityOTHER |
| 1 |
| Sep 17, 2019 |
| clinicaltrials |
| NCT02853903 | Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors | completed | Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02747537 | Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT03147976 | QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors | withdrawn | Phase 2 | 0 | NantPharma, LLCINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT01065805 | A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma | terminated | Phase 1 / Phase 2 | 94 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT03065023 | Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) | terminated | Phase 1 / Phase 2 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jul 30, 2019 | clinicaltrials |
| NCT00974168 | Spinal Cord Compression Re-Treat Study | completed | Phase 2 | 22 | Cancer Trials IrelandNETWORK | 1 | Jul 29, 2019 | clinicaltrials |
| NCT01858883 | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 55 | Incyte CorporationINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT04001569 | AZD8186 and Paclitaxel in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 49 | Seoul National University Bundang HospitalOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT02160041 | BGJ398 for Patients With Tumors With FGFR Genetic Alterations(CBGJ398XUS04) | terminated | Phase 2 | 84 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 18, 2019 | clinicaltrials |
| NCT03975036 | Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody | unknown | Phase 2 / Phase 3 | 100 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03166176 | Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy(TSC1/2_SC) | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT03166904 | Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy(RICTOR_SC) | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT03940820 | Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT00258180 | Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy | completed | Phase 2 | 3 | Johns Hopkins UniversityOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02048488 | A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 72 | Tesaro, Inc.INDUSTRY | 5 | Mar 26, 2019 | clinicaltrials |
| NCT01949688 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT00711243 | Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor | completed | Phase 1 / Phase 2 | 59 | Northwestern UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00814463 | Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases | terminated | Phase 2 | 1 | Duke UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01634555 | A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI | completed | Phase 2 | 29 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00390429 | Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | completed | Phase 1 / Phase 2 | 81 | University of California, DavisOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT02472977 | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors(CXCessoR4) | terminated | Phase 1 / Phase 2 | 61 | Bristol-Myers SquibbINDUSTRY | 2 | Nov 1, 2018 | clinicaltrials |
| NCT00389805 | Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | completed | Phase 1 / Phase 2 | 27 | University of California, DavisOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02352844 | Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations | completed | Phase 2 | 12 | Washington University School of MedicineOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03628131 | Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02787876 | Pegteograstim in Children With Solid Tumors | unknown | Phase 2 | 34 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01234922 | Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors | terminated | Phase 2 | 6 | Wake Forest University Health SciencesOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00002943 | Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer | completed | Phase 2 | 11 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT01015560 | S0916, MLN1202 in Treating Patients With Bone Metastases | completed | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 9, 2018 | clinicaltrials |
| NCT03615313 | PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor(PAEMCMPAST) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Aug 3, 2018 | clinicaltrials |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | completed | Phase 1 / Phase 2 | 110 | Puma Biotechnology, Inc.INDUSTRY | 9 | Jul 26, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT00074308 | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2018 | clinicaltrials |
| NCT00884312 | A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols | completed | Phase 2 | 101 | AmgenINDUSTRY | 2 | May 14, 2018 | clinicaltrials |
| NCT02884479 | An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | unknown | Phase 1 / Phase 2 | 75 | SciClone Pharmaceuticals International (Cayman) Development LimitedINDUSTRY | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01042535 | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT03439761 | An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 125 | SciClone PharmaceuticalsINDUSTRY | 1 | Mar 16, 2018 | clinicaltrials |
| NCT00095862 | Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers | terminated | Phase 1 / Phase 2 | 24 | Wiseman Research Initiatives LLCINDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00470548 | Abraxane and Alimta in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 49 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00810394 | Sorafenib in Treating Patients With Advanced Malignant Solid Tumors | completed | Phase 2 | 50 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT03389815 | A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 48 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 4, 2018 | clinicaltrials |
| NCT03266159 | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 8, 2017 | clinicaltrials |
| NCT00389584 | Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors | completed | Phase 1 / Phase 2 | 30 | University of California, DavisOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02100007 | ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | MEI Pharma, Inc.INDUSTRY | 2 | Oct 2, 2017 | clinicaltrials |
| NCT01227954 | Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases | completed | Phase 2 | 113 | Radiation Therapy Oncology GroupNETWORK | 2 | Sep 27, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Sep 26, 2019source: clinicaltrials